Vision Executives’ Post

The global #medtech industry approaches 2025 with a strong sense of optimism, driven by rapid innovation as well as new programs to help streamline FDA & OUS regulatory processes, are helping more new medtech reach patients across the globe. Increased global #investment into AI/ML empowered #digitalhealth, advanced #imaging, #roboticsurgery, as well as #vascular intervention highlight the sector’s resilience and adaptability. Here are a few of this week’s key events across the global medtech area: 🟢The team at myBiometry, announce $5M in new oversubscribed seed fund led by Dexcom Ventures. This latest financing round will support their next stages of development and clinical studies toward their fenoTRACK device, a portable non-invasive breath test for airway inflammation diagnostics through fractional exhaled nitric oxide (FeNO) 🟢Momentis Surgical™ out of Israel & Ft Lauderdale announces FDA 510(k) clearance toward their 2nd gen, Anovo surgical robot, offering physicians more enhancment from haptic feedback as well as dual-mode articulation. This latest FDA win adds on to their initial approval for transvaginal benign gynecology procedures. 🟢EndoQuest Robotics™ in Houston, TX announces FDA IDE approval to begin clinical trials their their robotic assisted endoluminal surgical platform for up and lower GI procedures. 🟢Exciting announcements from Inspire Medical Systems in Minnesota as they more forward with their accelerated share repurchase (ASP) program partnering with Goldman Sachs to reaquire roughly $75 million worth of Inspire Medical common stack. 🟢Otsuka Pharmaceutical Companies (U.S.) partners with ICU Medical to enter U.S. IV products market helping offer substantial assistance toward rapidly IV manufacturing capabilities to north of 1.4B units produced annually alongside assistance in supply chain optimization 🟢Bay area’s own, ZAP Surgical Systems, Inc., announces $78M in new successful financial raise toward flagship, ZAP-X platform, a robotic device toward non-invasive stereotactic radiosurgery (SRS) procedures to treat brain tumours, lesions, and other conditions of the head and neck 🟢Irvine, California-based JenaValve Technology, Inc. receive permission to begin their ARTIST trial, slated for Q1 2025 examing both non-high-risk patients vs moderate-to-severe as well as severe AR treated with Trilogy undergoing surgical aortic valve replacement (SAVR). **STORY OF THE WEEK** 🟢Johnson & Johnson MedTech announces successful IDE approval toward their multi-arm robotic minimally invasive laparoscopic surgical platform, the OTTAVA. Next steps will bring the OTTAVA into clinical studies as well as furthering next steps toward US & OUS commercialization. Very encouraged and excited to see the continued momentum spreading across the global medtech spectrum late into 2024 with strong aspirations as we closer into the new year. Have a great weekend!🌅

Check out the latest report from IMIR Market Research Pvt. Ltd. on the 𝗦𝘁𝗲𝗿𝗲𝗼𝘁𝗮𝗰𝘁𝗶𝗰 𝗦𝘂𝗿𝗴𝗲𝗿𝘆 𝗗𝗲𝘃𝗶𝗰𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 Outlook and Geography Forecast till 2028 Don't miss out on this opportunity to stay informed about the latest trends in the industry. Stereotactic Surgery Devices Market Size, Share & Trends Analysis Report By Equipment Type (The gamma knife, Line accelerator (LINAC) machines), By Applications (Brain tumor treatment, Arteriovenous malformations treatment, Parkinsons disease, Epilepsy, Others (trigeminal neuralgia)), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028. Global Stereotactic Surgery Devices Market size was valued at USD 18.97 Billion in 2021 and is projected to reach USD 25.62 Billion by 2028, growing at a CAGR of 4.75% from 2021 to 2028 according to a new report by Intellectual Market Insights Research. 📚 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗳𝗿𝗲𝗲 𝘀𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝗽𝗼𝗿𝘁:👇 https://lnkd.in/dF7dyyRr Mevion Medical Systems, Varian Medical Systems Particle Therapy GmbH, Monteris Medical, Elekta  Micromar, Accuracy Plus Medical Laboratory, inomed, pfm medical gmbh. Huiheng Medical Inc  Siemens Elekta  IBA Accuray adeor medical AG,  Monteris Medical,  Elekta  RaySearch Laboratories,  inomed,  Micromar Elekta  Ion Beam Services  Mevion Medical Systems inomed pfm medical gmbh Monteris Medical

👁️ 𝐀𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐂𝐨𝐫𝐧𝐞𝐚 𝐓𝐫𝐚𝐧𝐬𝐩𝐥𝐚𝐧𝐭: 𝐀 𝐆𝐚𝐦𝐞-𝐂𝐡𝐚𝐧𝐠𝐞𝐫 𝐟𝐨𝐫 𝐆𝐥𝐨𝐛𝐚𝐥 𝐁𝐥𝐢𝐧𝐝𝐧𝐞𝐬𝐬 CorNeat Vision's 𝐊𝐏𝐫𝐨 𝐚𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐢𝐦𝐩𝐥𝐚𝐧𝐭, successfully tested on a 78-year-old patient, represents a breakthrough in treating corneal blindness—a condition affecting millions worldwide. With its innovative design and simplified surgical approach, this technology has the potential to transform eye care for patients in regions where corneal donation is scarce. 🛠️ 𝐖𝐡𝐚𝐭 𝐒𝐞𝐭𝐬 𝐓𝐡𝐢𝐬 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐀𝐩𝐚𝐫𝐭? ✅ 𝐍𝐚𝐧𝐨-𝐓𝐢𝐬𝐬𝐮𝐞 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲: The implant uses non-degradable synthetic nano-tissue that integrates seamlessly with the eye, promoting cell proliferation. ✅ 𝐒𝐢𝐦𝐩𝐥𝐞𝐫 𝐒𝐮𝐫𝐠𝐞𝐫𝐲: Unlike earlier synthetic corneas, this implant requires minimal cutting and suturing, significantly reducing procedure time and complexity. ✅ 𝐈𝐦𝐦𝐞𝐝𝐢𝐚𝐭𝐞 𝐑𝐞𝐬𝐮𝐥𝐭𝐬: The patient, Jamal Furani, regained his sight the very next day, recognizing relatives and even reading texts. ✅ 𝐁𝐫𝐨𝐚𝐝 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥: Ideal for patients with deformed, opaque, or scarred corneas, particularly in areas with limited access to donor tissue. 🌍 𝐆𝐥𝐨𝐛𝐚𝐥 𝐈𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 The success of this technology could revolutionize treatment by eliminating reliance on donor tissue, addressing critical shortages worldwide. Clinical trials are expanding, with patients from Israel, Canada, France, the U.S., and the Netherlands participating. 🔮 𝐖𝐡𝐚𝐭’𝐬 𝐍𝐞𝐱𝐭? With continued trials and international interest, the KPro implant could soon become a vital solution for millions. As the technology matures, its adoption in underserved regions could make corneal blindness a thing of the past. 𝐃𝐨 𝐲𝐨𝐮 𝐭𝐡𝐢𝐧𝐤 𝐭𝐡𝐢𝐬 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐰𝐢𝐥𝐥 𝐫𝐞𝐩𝐥𝐚𝐜𝐞 𝐭𝐫𝐚𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐜𝐨𝐫𝐧𝐞𝐚𝐥 𝐭𝐫𝐚𝐧𝐬𝐩𝐥𝐚𝐧𝐭𝐬 𝐞𝐧𝐭𝐢𝐫𝐞𝐥𝐲, 𝐨𝐫 𝐰𝐢𝐥𝐥 𝐢𝐭 𝐫𝐞𝐦𝐚𝐢𝐧 𝐚 𝐜𝐨𝐦𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐚𝐫𝐲 𝐨𝐩𝐭𝐢𝐨𝐧? 🔍 𝐅𝐨𝐥𝐥𝐨𝐰 👉 Robert 지영 Liebhart for updates on groundbreaking medical technology and how innovation is changing lives globally. 𝐂𝐫𝐞𝐝𝐢𝐭𝐬: Alexey Navolokin

Great news from the German market! Protembis GmbH has received s €20 million investment from The European Investment Bank. The funding is to support clinical trials, research, development and market access for the “ProtEmbo” cerebral embolic protection system. TAVR is an x-ray guided procedure to replace an aortic valve that has narrowed and doesn't open fully. TAVR is minimally invasive, meaning it uses smaller incisions than open-heart valve surgery. Globally, around 430,000 patients with severe aortic stenosis are expected to be treated with TAVR by 2025. ProtEmbo is inserted during TAVR via the artery in the left wrist, and lines the roof of the aortic arch, shielding the brain from the dislodged debris. #medtech #healthinnovation #europeaninvestments

AVASA (LSI Europe ‘24 Innovator) is setting a new global standard in microsurgery with its revolutionary Avasa Coupler. Designed to simplify and accelerate arterial connections during free flap surgeries, the device eliminates the need for time-consuming, high-risk hand sewing, allowing plastic surgeons to streamline reconstructive procedures for patients with physical deformities caused by cancer treatment, trauma, or congenital conditions. Now raising its Series A to bring this innovation to market, Avasa has achieved several important milestones: • Filed patents in key markets, positioning the company to expand into other high-value surgeries in the future. • Preclinical studies show the Avasa Coupler is 80% faster than the manual sewing method, with a 0% failure rate compared to the 4% typically seen in microsurgery. • Market research reveals strong demand, with 89% of over 100 surgeons surveyed eager to use an arterial coupler, and 88% predicting it will become the new standard of care for arterial connections. • Coding, coverage, and payment are already in place, with hospitals expected to see significant cost savings. • Leading KOLs from Harvard, MD Anderson, and Stanford are backing the product, helping drive market adoption. We’re excited to announce that Founder & CEO, Nandoun Abeysekera has been selected to present Avasa at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Nandoun and learn more about Avasa.

What if endometriotic lesions could be removed with novel medicines instead of surgery? What if new imaging methods could replace laporoscopic surgery for the definitive diagnosis of endometriosis? What if biomarkers could diagnose endometriosis early? Did you know endometriosis affects over 10% of women during their reproductive years, significantly impacting their quality of life? Our new White Paper explores the critical need for non-hormonal treatment options for endometriosis and adenomyosis. Despite the high prevalence, new therapies are lacking, with current treatments being either hormonal or invasive, representing a high cost to patients and society. The Artemis Women's Health Foundation and Catenion  have created a comprehensive guide for startups, investors and pharma companies who want to change the status quo and bring innovative treatments to Endometriosis and Adenomyosis patients. Ready to learn more? Download our White Paper now: https://lnkd.in/e3aNdA4x  #ArtemisWomensHealthFoundation #Endometriosis #WomensHealth #MedicalInnovation #NonHormonalTreatments #Adenomyosis #Innovation #Healthcare #DownloadNow Gesynta Pharma AB, Maipl Therapeutics, Inc. FimmCyte, Serac Healthcare, Hera Biotech Xena Dx (Techstars '23) Heranova Lifesciences Scanvio Medical MiMARK Diagnostics DotLab curE-me, Fiftyone Bio

Endometriosis care is evolving. Women with endometriosis have long faced limited options: hormonal treatments with side effects or invasive surgery. Both take a toll — physically, emotionally, and financially. But change is finally on the horizon. The Artemis Women's Health Foundation and Catenion have released a White Paper that highlights the growing need for non-hormonal treatment options for both Endometriosis and Adenomyosis. It serves as a guide for Startups, Investors, and Pharma companies looking to transform care and bring innovative solutions to those who need them most. At Scanvio Medical, we share this mission. Our work focuses on advancing solutions that prioritize early, accessible, and patient-focused care for women’s health. Awareness is the first step toward change. We are proud to stand alongside a community dedicated to rethinking what care for women can and should be. It is inspiring to see so many innovators driving progress, and we are excited to be part of this movement. Thank you for including us in this essential dialogue. We look forward to continuing this journey toward better health outcomes for women. 👉 Discover the full White Paper here: https://lnkd.in/e3aNdA4x #ArtemisWomensHealthFoundation #ScanvioMedical #Endometriosis #WomensHealth #MedicalInnovation #NonHormonalTreatments #AIforUltrasound #Innovation #Healthcare

Plexāā | Creators of BLOOM⁴³ collaborates with Panasonic to manufacture BLOOM⁴³ medical device. The BLOOM⁴³ platform helps patients prepare for breast cancer surgery and reconstruction—with a technique that has been shown to reduce wound healing. With over 1 million breast surgeries performed annually in the US alone, this collaboration will accelerate the production and scaling—with first products expected early this year. #endcancer #womenshealth #medicaladvancement https://lnkd.in/ecVAxtff